AveXis, for example, said it would be using the funds for a clinical trial and future spinal muscular atrophy trials. And it seems investors are more willing to invest in biotech companies, while staying away from others, because of the value they ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.